Reduction of animal suffering in rabies vaccine potency testing by introduction of humane endpoints
By Mutsuyo Takayama-Ito - Chang-Kweng Lim - Kazuo Nakamichi - Satsuki Kakiuchi - Madoka Horiya - Guillermo Posadas-Herrera - Ichiro Kurane - Masayuki Saijo
| Record number: | 5646904 |
|---|---|
| Category: | humane endpoints - vaccines - vaccine development - animal welfare - body weight changes - rabies - death - mice - laboratory animals - paralysis - coma - Rabies virus - body temperature |
Potency controls of inactivated rabies vaccines for human use are confirmed by the National Institutes of Health challenge test in which lethal infection with severe neurological symptoms should be observed in approximately half of the mice inoculated with the rabies virus. Weight loss, decreased body temperature, and the presence of rabies-associated neurological signs have been proposed as humane endpoints. The potential for reduction of animal suffering by introducing humane endpoints in the potency test for inactivated rabies vaccine for human use was investigated. The clinical signs were scored and body weight was monitored. The average times to death following inoculation were 10.49 and 10.99 days post-inoculation (dpi) by the potency and challenge control tests, respectively, whereas the average times to showing Score-2 signs (paralysis, trembling, and coma) were 6.26 and 6.55 dpi, respectively. Body weight loss of more than 15% appeared at 5.82 and 6.42 dpi. The data provided here support the introduction of obvious neuronal signs combined with a body weight loss of ≥15% as a humane endpoint to reduce the time of animal suffering by approximately 4 days.
Issued: March 2017
Journal Title: Biologicals
ISSN: 1045-1056
Volume issue: 46 v.
Pages: 38 - 45
Publisher: Elsevier Ltd
AGRICOLA identifier: IND605646904
DOI identifier: 10.1016/j.biologicals.2016.12.007
Takk for din tilbakemelding! Vær oppmerksom på at vi ikke kan kontakte deg hvis ikke du oppgir din epostadresse.
Hva lette du etter?
Gi oss gjerne en tilbakemelding slik at vi kan forbedre informasjonen på siden. På forhånd takk for hjelpen! Vennligst skriv inn din epostadresse hvis du vil ha et svar.
Kontakt oss gjerne på e-post hvis du har spørsmål.